Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.
Also called NCT03786757
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT03786757
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT03786757. Randomized; no masking; primary purpose prevention. Start 2019-04-01 (anticipated); primary completion 2022-03-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)
- Condition
- ST Segment Elevation Myocardial Infarction
- Condition
- Left Ventricular Thrombus
- Intervention (Drug)
- Rivaroxaban
- Lead sponsor
- RenJi Hospital
Record details
- Record id
cardio:ct-nct03786757- Content hash
5decfa0cdc48448f42af4a96875023a11ed835aae9453b0ddd6b3d0e7ba07521